SK Biopharmaceuticals Co., Ltd. Stock: price and insider trades · South Korea
에스케이바이오팜
2 insiders bought €135k of shares over the last 90 days, the latest by 이동훈, filed 31 Aug 2026.
SK Biopharmaceuticals Co., Ltd.: what insiders have been doing
SK Biopharmaceuticals Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). Over the twelve months to 31 October 2026, 8 filings were filed, from 7 insiders.
Purchases and sales both appear in the filings: 3 purchases (3 insiders, €718.7M) and 3 sales (3 insiders). The totals exclude 5 filings filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €718.7M, the purchase published on 31 March 2026 by Sk is the largest of the period (18.6% of market cap). The buyers include 1 senior executive and 1 chief executive.
The last insider purchase was made public on 31 August 2026, 71 days ago. Filings reach the DART (FSS) feed a median of 1 day after the trade. This delay matters because a trade only becomes useful information once it is public.
With 8 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Since 2021, the database holds 10 purchases and 3 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -21.5%Entry ₩99,000 · Close 30 Oct 2026 ₩77,700
- +30.4%Entry ₩73,300 · Close at T+365 ₩95,600
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 2,000 sharesShareKRXDART:20260831000159Canonical exit: 29 Nov 2026 (T+90)
- 500 sharesShareKRXDART:20260831000145Canonical exit: 29 Nov 2026 (T+90)
- 808,452 sharesKRXDART:20260401003967
- 10,923,927 sharesKRXDART:20260331003595
- 10,917,028 shares@ ₩114,500.0018.55% mcap100.0% of flowShareKRXDART:20260331003378Canonical exit: 28 Jun 2026 (T+90)
- ●Executives0DART
- 3,280 sharesKRXDART:20260226006568
- ShareKRXDART:20260226006746
- 788,245 sharesKRXDART:20251001000642Canonical exit: 14 Dec 2025 (T+90)
- 4,500 sharesShareKRXDART:20250106000207Canonical exit: 6 Apr 2025 (T+90)
- ShareKRXDART:20230908000051
- ShareKRXDART:20230731000165
- ShareKRXDART:20230524000161
- ShareKRXDART:20230421000070
- 788,245 sharesKRXDART:20230404000542Canonical exit: 3 Jul 2023 (T+90)
- ●Executives0DART
- 3,000 shares@ ₩70,100.00100.0% of flowShareKRXDART:20230106000048Canonical exit: 6 Apr 2023 (T+90)
- ●Executives0DART
- ShareKRXDART:20211229000348
- ShareKRXDART:20211208000179
- ShareKRXDART:20211012000381
- 788,245 sharesKRXDART:20211006000212Canonical exit: 4 Jan 2022 (T+90)
- ShareKRXDART:20210727000235
25 of 40 declarations
About SK Biopharmaceuticals Co., Ltd.
SK Biopharmaceuticals is a company in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative treatments for neurological and psychiatric disorders.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
